MentalHealthDaily

Inflammatory Depression Had Higher Kynurenine Metabolites

by GLOOM

A 2026 biomarker study found kynurenine-pathway activation in inflammatory major depressive disorder (MDD), but not across all depression cases. Compared with non-inflammatory MDD and healthy controls, the inflammatory subgroup had higher pathway metabolites, and omega-3 treatment reduced several of them over 8 weeks.1 Research Highlights Inflammatory depression showed kynurenine activation: people with MDD and high-sensitivity …

Anxiety Biomarkers: gp130, MMP-1, APRIL in 190 Adults

by GLOOM

Stylized illustration of an anxious silhouette overlaid with vials and three biomarker labels (gp130, MMP-1, APRIL), representing the inflammation-anxiety biomarker associations in the Cancer Disparities Research Network cohort.

The link between psychological stress and chronic inflammation is well-documented — what’s been less clear is which specific inflammatory proteins move with anxiety in real-world community samples. A 2026 analysis from Loomans-Kropp et al. measured a 33-marker panel in 190 minoritized and medically underserved adults from the Cancer Disparities Research Network and identified three biomarkers …

High Cytokines Predicted Weaker Placebo Response in Cancer Symptom Trial

by GLOOM

MHD featured image for cytokine biomarkers and placebo response in cancer symptom trials.

A 2026 exploratory analysis of the ABCD cancer dyspnea trial found that higher baseline cytokines predicted less placebo symptom improvement than lower baseline cytokines across 33 of 40 cytokine-symptom combinations at day 7 and 29 of 40 at day 14.1 The signal is not ready for clinical prediction, but it sharpens a trial-design problem: patients …

Alpha-Synuclein SAA Predicts Parkinson’s Levodopa Response Durability

by GLOOM

Photoreal illustration of CSF biomarker testing alongside dopaminergic neuron pathways, representing PD biomarker stratification.

A 2026 PPMI analysis found that Parkinson’s patients with positive CSF α-synuclein seed amplification assay results kept gaining levodopa benefit over follow-up, while SAA-negative patients showed faster ON-medication motor progression than SAA-positive patients: 0.87 vs. 3.47 MDS-UPDRS Part III points/year in 183 matched SAA-positive and 40 SAA-negative patients.1 Research Highlights ON-state progression split sharply: SAA-positive …

Peripheral Inflammatory Biomarkers vs. Suicide Risk in Major Depression (2024 Study)

by GLOOM

Major Depressive Disorder (MDD) is not just a mental health concern; it’s a complex interplay of psychological, environmental, and biological factors, where the most tragic outcome can be suicide. Recent research has unveiled a potential link between the immune system’s inflammatory response and the increased risk of suicide among those suffering from MDD. By examining …

Sleep Disorders vs. Systemic Immune-Inflammation Index (SII) in the U.S. Population (2023 Study)

by GLOOM

Sleep and inflammation have long been topics of scientific inquiry, with a growing body of evidence underscoring their intricate relationship. The systemic immune-inflammation index (SII), a novel marker based on leukocyte parameters, has emerged as a significant indicator of systemic inflammation. A recent study explored the association between sleep-related disorders and SII, revealing intriguing connections …

Abnormal Brain EEG Activity Doesn’t Predict Antidepressant Efficacy in Depression (2023 Study)

by GLOOM

Depression is a multifaceted mental health condition that presents significant challenges in both diagnosis and treatment. Recent studies have explored the potential of electroencephalography (EEG) as a predictive tool for treatment outcomes in major depressive disorder (MDD), with particular focus on the response to antidepressants like escitalopram. Highlights: EEG Abnormalities & Antidepressant Response: Contrary to …